Who are the key players in US Direct-to-Consumer Laboratory Testing industry?

The top 5 players in the US Direct-to-Consumer Laboratory Testing industry are 23andMe, Everlywell, LetsGetChecked, LabCorp, and Quest Diagnostics. These companies offer a range of testing services, from genetic and health testing to wellness screenings, providing consumers easy and direct access to laboratory results.

What is the US Direct-to-Consumer Laboratory Testing growth?

The US Direct-to-Consumer Laboratory Testing market has seen rapid growth, with Everlywell experiencing significant revenue increases in 2023 due to rising at-home health awareness, telehealth adoption, and expanded testing portfolios. Market momentum is driven by consumer demand for convenient, affordable, and private medical testing solutions.

Which segment accounted for the largest US Direct-to-Consumer Laboratory Testing share?

The health and wellness testing segment holds the largest market share in US DTC lab testing, led by demand for tests like food sensitivity, general wellness, and hormone testing. Everlywell and similar companies have popularized these offerings with user-friendly kits, contributing to their dominance in this application category.

What are the factors driving the US Direct-to-Consumer Laboratory Testing?

Key growth drivers include rising consumer health awareness, accessibility of digital health platforms, and regulatory support. For example, in 2023, Quest Diagnostics expanded its online platform, allowing more individuals to access tests without physician referrals, making health tracking more personalized, private, and convenient.

Which type accounted for the largest US Direct-to-Consumer Laboratory Testing share?

Sample collection kits, particularly for blood and saliva testing, accounted for the largest share of the US DTC laboratory testing market. Companies like 23andMe and LetsGetChecked have streamlined these processes, making at-home collection simple and accurate for health, genetic, and wellness-related testing.

Home Telecommunication

US Direct-to-Consumer Laboratory Testing Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: US Direct-to-Consumer Laboratory Testing
Brand: Bussiness Insights

US Direct-to-Consumer Laboratory Testing Market: by Type (Genetic Testing, Disease Risk Assessment, Wellness & Fitness Testing, Ancestry & Relationship Testing, Food Sensitivity Testing, Drug Testing), Application (Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology, Others), Distribution Channels (Online Platforms, Retail Pharmacies, Clinics, Hospitals, Direct Sales, Others), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunoassays, Microarrays, Mass Spectrometry, Others), Organization Size (Small, Medium, Large) and By US Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 12-09-2025 | Format: PDF | Report ID:21119

US Direct-to-Consumer Laboratory Testing Market Outlook and Forecast (2025-2035)

The US direct-to-consumer laboratory testing market is experiencing rapid growth, driven by heightened demand for personalized healthcare solutions and increased accessibility to diagnostic platforms. As consumer awareness regarding preventative health rises, companies are innovating with new test offerings spanning genetic, wellness, disease risk, and ancestry-related panels, delivered through seamless digital and retail channels. The sector is forecasted to witness substantial revenue escalation through 2035 as regulatory clarity, investment in digital health, and strategic partnerships strengthen market confidence.

Latest Market Dynamics

Key Drivers

Surging consumer demand for convenient and private health insights is a significant growth catalyst. For instance, in early 2024, Everlywell announced expanded at-home lab offerings tailored to chronic disease monitoring, reflecting the broader trend towards patient-driven health management.

Integration of artificial intelligence for result interpretation and personalized health recommendations. In June 2024, 23andMe unveiled an AI-powered dashboard to interpret genetic test outcomes, aiding users in actionable next steps.
Rising partnerships between retailers and lab testing companies. Walgreens and LabCorp, in July 2024, expanded in-pharmacy testing services to cover broader wellness and chronic disease panels, improving accessibility.

Expansion of carrier screening and disease-specific panels for underserved populations. Color Genomics launched an expanded hemoglobinopathies panel in August 2024, addressing unmet needs in genetic risk assessment.
Growth in preventive and proactive health management. Quest Diagnostics, June 2024, introduced annual health screening subscriptions for wellness-minded consumers, tapping into ongoing lifestyle health trends.

Data privacy and security concerns. With increased use of digital platforms, companies like Helix have seen greater scrutiny over data handling protocols, necessitating substantial investments in cybersecurity.
Regulatory uncertainty regarding test validation. Myriad Genetics reported delays in 2024 due to evolving FDA guidance, highlighting the regulatory challenges for test approvals and consumer marketing.

Low health literacy and skepticism about test accuracy remain barriers. In response, companies such as WellnessFX are focusing on consumer education to clarify testing limitations and benefits.
High out-of-pocket costs for comprehensive panels deter some segments. Even with direct access, some consumers forgo broader panels due to price sensitivity, prompting labs like Genova Diagnostics to pilot tiered pricing schemes.

In 2025, the market is segmented by major testing types including genetic testing, disease risk assessment, wellness & fitness, ancestry & relationship, food sensitivity, and drug testing. Genetic testing dominates with 38% due to increased consumer focus on ancestry, carrier screening, and hereditary disease risk. Wellness & fitness testing follows at 24%, benefitting from preventive health trends and personalized fitness regimens. Disease risk assessment holds 16%, ancestry & relationship testing 12%, food sensitivity 6%, and drug testing 4%, reflecting a balanced but concentrated preference for genetic and lifestyle-related panels.

By application, oncology leads with 27% of the market as cancer risk panels gain prominence for early detection and prevention. Cardiology testing captures 22% as cardiovascular health awareness increases. Infectious diseases testing is at 18%, in part due to the ongoing demand for at-home screening following the pandemic. Neurology comprises 13%, endocrinology holds 11%, and other applications together represent 9%. This breakdown emphasizes consumer interest in proactive disease risk assessment alongside wellness monitoring.

The US direct-to-consumer laboratory testing market is projected to expand from 2,700 Million USD in 2020 to 9,200 Million USD by 2035. The steady year-on-year growth is driven by rising consumer awareness, improvements in testing technologies, regulatory support, and the proliferation of digital health platforms. Notably, rapid acceleration is observed from 2024 onward as major retailers and telehealth companies integrate diagnostics into their health offerings.

Regional distribution highlights the concentration of direct-to-consumer lab testing in key economic and population centers. The West region, with states such as California, leads at 34%, driven by tech-savvy populations and higher adoption rates. The South follows at 27%, supported by large metropolitan markets. The Midwest and Northeast capture 21% and 18% respectively, anchored by urban health systems and rising consumer engagement.

In 2025, the market remains fragmented, yet dominated by a handful of key companies. 23andMe holds 21% of the share due to its leadership in genetic testing. LabCorp and Quest Diagnostics together represent 29%, leveraging their extensive testing infrastructure. Everlywell captures 13% as a standout digital-first provider. LetsGetChecked sees an 8% share, while other players including Myriad Genetics, Color Genomics, and regional specialists collectively account for 29%.

Market segmentation by buyer sees health-conscious consumers leading with 46% of purchases, driven by proactive wellness and genetic interest. Families and caregivers represent 24%, as they turn to at-home tests for family health screening. Chronically ill patients make up 17%, using at-home monitoring for disease management, while corporate clients such as employers and insurers account for 8%. The remaining 5% is split across wellness clinics and research buyers.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	4000
Regions	West, South, Midwest, Northeast
Segments	Genetic Testing, Disease Risk Assessment, Wellness & Fitness Testing, Ancestry & Relationship Testing, Food Sensitivity Testing, Drug Testing, Oncology, Cardiology, Neurology, Infectious Diseases, Endocrinology, Others
Players	23andMe, LabCorp, Quest Diagnostics, Myriad Genetics, Everlywell, LetsGetChecked, Color Genomics, WellnessFX, Direct Laboratory Services, Helix, Pathway Genomics, DNA Direct, Genova Diagnostics, MedGenome, Veritas Genetics

June 2024: Quest Diagnostics partners with major health insurer to roll out comprehensive at-home annual health panels, expanding preventive testing access.
July 2024: 23andMe releases an AI-driven interpretation engine on its platform, providing personalized health action plans derived from genetic data.
August 2024: Color Genomics launches an expanded carrier screening test with coverage for hemoglobinopathies in underserved populations.
September 2024: Walgreens and LabCorp expand in-pharmacy testing to new states, broadening consumer access to affordable diagnostic panels.
October 2024: Everlywell unveils next-gen at-home cardiovascular risk assessment kit, integrating mobile app-guided sample collection and results delivery.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

US Direct-to-Consumer Laboratory Testing Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

US Direct-to-Consumer Laboratory Testing Market Outlook and Forecast (2025-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

US Direct-to-Consumer Laboratory Testing Market Share by Type, 2025

US Direct-to-Consumer Laboratory Testing Market Share by Applications, 2025

US Direct-to-Consumer Laboratory Testing Market Revenue (USD Million), 2020-2035

US Direct-to-Consumer Laboratory Testing Market YoY Growth (%), 2020-2035

US Direct-to-Consumer Laboratory Testing Market Share by Regions (%), 2025

US Direct-to-Consumer Laboratory Testing Market Players Share (%), 2025

US Direct-to-Consumer Laboratory Testing Market Buyers Share (%), 2025

Study Coverage

Key Recent Developments

Frequently asked questions